Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Industry influence on comparative-effectiveness research funded through health care reform.

Selker HP, Wood AJ.

N Engl J Med. 2009 Dec 31;361(27):2595-7. doi: 10.1056/NEJMp0910747. Epub 2009 Nov 18. No abstract available.

2.

Off-label prescribing: a call for heightened professional and government oversight.

Dresser R, Frader J.

J Law Med Ethics. 2009 Fall;37(3):476-86, 396. doi: 10.1111/j.1748-720X.2009.00408.x.

3.

The promotion of olanzapine in primary care: an examination of internal industry documents.

Spielmans GI.

Soc Sci Med. 2009 Jul;69(1):14-20. doi: 10.1016/j.socscimed.2009.05.001. Epub 2009 May 27.

PMID:
19481322
4.

Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.

Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D.

JAMA. 2009 Apr 1;301(13):1367-72. doi: 10.1001/jama.2009.407.

PMID:
19336712
5.

The marketing of osteoporosis.

Napoli M.

Am J Nurs. 2009 Apr;109(4):58-61. doi: 10.1097/01.NAJ.0000348606.24360.7d. Review. No abstract available.

PMID:
19325320
6.

The spurious advance of antipsychotic drug therapy.

Tyrer P, Kendall T.

Lancet. 2009 Jan 3;373(9657):4-5. doi: 10.1016/S0140-6736(08)61765-1. Epub 2008 Dec 6. No abstract available.

PMID:
19058841
7.

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL.

Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070. Review.

8.

Impugning the integrity of medical science: the adverse effects of industry influence.

DeAngelis CD, Fontanarosa PB.

JAMA. 2008 Apr 16;299(15):1833-5. doi: 10.1001/jama.299.15.1833. No abstract available.

PMID:
18413880
9.

Regulating off-label drug use--rethinking the role of the FDA.

Stafford RS.

N Engl J Med. 2008 Apr 3;358(14):1427-9. doi: 10.1056/NEJMp0802107. No abstract available.

10.

Drug-review deadlines and safety problems.

Carpenter D, Zucker EJ, Avorn J.

N Engl J Med. 2008 Mar 27;358(13):1354-61. doi: 10.1056/NEJMsa0706341.

11.

Reflecting on type 2 diabetes prevention: more questions than answers!

Rosenstock J.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:3-11. Review.

PMID:
17877541
12.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

13.

A national survey of physician-industry relationships.

Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D.

N Engl J Med. 2007 Apr 26;356(17):1742-50.

14.

Characteristics and impact of drug detailing for gabapentin.

Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA.

PLoS Med. 2007 Apr;4(4):e134.

15.

Are lipid-lowering guidelines evidence-based?

Abramson J, Wright JM.

Lancet. 2007 Jan 20;369(9557):168-9. No abstract available.

PMID:
17240267
16.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770.

17.

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators.

N Engl J Med. 2006 Apr 20;354(16):1685-97. Epub 2006 Mar 14.

18.

Health industry practices that create conflicts of interest: a policy proposal for academic medical centers.

Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, Smelser N.

JAMA. 2006 Jan 25;295(4):429-33.

PMID:
16434633
19.

Is there time for management of patients with chronic diseases in primary care?

Østbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL.

Ann Fam Med. 2005 May-Jun;3(3):209-14.

20.
Items per page

Supplemental Content

Write to the Help Desk